Qualitative Imaging of Adeno-Associated Virus Serotype 2–Human Aromatic L-Amino Acid Decarboxylase Gene Therapy in a Phase I Study for the Treatment of Parkinson Disease
- 1 November 2010
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurosurgery
- Vol. 67 (5), 1377-1385
- https://doi.org/10.1227/neu.0b013e3181f53a5c
Abstract
Putaminal convection-enhanced delivery (CED) of an adeno-associated virus serotype 2 (AAV2) vector, containing the human aromatic L-amino acid decarboxylase (hAADC) gene for the treatment of Parkinson disease (PD), has completed a phase I clinical trial. To retrospectively analyze magnetic resonance imaging (MRI) and positron emission tomography (PET) data from the phase I trial, correlate those data with similar nonhuman primate (NHP) data, and present how such information may improve future PD gene therapy trials in preparation for the initiation of the phase II trial. Ten patients with PD had been treated with bilateral MRI-guided putaminal infusions of AAV2-hAADC. MRI and PET scans were obtained at baseline (before vector administration) and at various intervals after treatment. Three normal adult NHPs received similar infusions into the thalamus. Imaging studies for both groups are presented, as well as hAADC immunohistochemistry for the NHPs. Early post-CED MRI confirmed the stereotactic targeting accuracy and revealed T2 hyperintensity around the distal cannula tracts, best seen within 4 hours of surgery. Coregistration of post-CED MRI and PET scans revealed increased PET uptake at the sites of T2 hyperintensity. Similar T2 hyperintensities in NHP MRI correlated with hAADC immunohistochemistry. Our analysis confirms the correct targeting of the CED cannula tracts within the target human putamen. Coregistration of MRI and PET confirms colocalization of T2 hyperintensities and increased PET uptake around the distal cannula tracts. Because PET uptake closely correlates with hAADC transgene expression and NHP data confirm this relationship between T2 hyperintensity and hAADC immunohistochemistry, we believe that T2-weighted MRI allows visualization of a significant part of the distribution volume of the hAADC gene therapy. Recommendations for future protocols based on these data are presented.Keywords
This publication has 28 references indexed in Scilit:
- Safety and tolerability of putaminal AADC gene therapy for Parkinson diseaseNeurology, 2009
- Real-time MR imaging of adeno-associated viral vector delivery to the primate brainNeuroImage, 2009
- Striatal volume differences between non-human and human primatesJournal of Neuroscience Methods, 2009
- Detection of infusate leakage in the brain using real-time imaging of convection-enhanced deliveryJournal of Neurosurgery, 2008
- Biodistribution of Adeno-associated Virus Type-2 in Nonhuman Primates after Convection-enhanced Delivery to BrainMolecular Therapy, 2008
- Safety of real-time convection-enhanced delivery of liposomes to primate brain: A long-term retrospectiveExperimental Neurology, 2008
- Antiparkinson ProdrugsMolecules, 2008
- A Dose-Ranging Study of AAV-hAADC Therapy in Parkinsonian MonkeysMolecular Therapy, 2006
- Convection-Enhanced Delivery of Adeno-Associated Virus Type 2 (AAV2) into the Striatum and Transport of AAV2 Within Monkey BrainHuman Gene Therapy, 2006
- Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brainExperimental Neurology, 2005